COMMUNIQUÉS West-GlobeNewswire
-
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
16/09/2025 -
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
16/09/2025 -
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
16/09/2025 -
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
16/09/2025 -
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
16/09/2025 -
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
16/09/2025 -
Sharecare, AWS, CLEAR, and Georgia Department of Community Health to discuss bringing CMS’s health tech ecosystem vision to life at Health Connect South
16/09/2025 -
PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A
16/09/2025 -
Cirtec Medical Welcomes Chris Cleary to its Board of Directors
16/09/2025
Pages